Rigel Pharmaceuticals Inc. (RIGL) intrinsic value & 10-year financials
Rigel Pharmaceuticals Inc. (RIGL) has a Graham intrinsic value of $647.04 per share. At $45.97 on Oct 17, 2026, the stock trades 93% below that value. Over the last 10 fiscal years revenue grew 34.5% a year to $294.3M, with an average return on invested capital of -281.2%.
- Graham intrinsic value
- $647.04
- Share price (Oct 17, 2026)
- $45.97
- Price vs Graham value
- 93% below
- Market cap
- $866.1M
- Revenue (FY2025)
- $294.3M
- Revenue growth (10-yr CAGR)
- 34.5%
- ROIC (10-yr avg)
- -281.2%
- Free cash flow (FY2025)
- —
RIGL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $294.3M | $367.0M | $19.48 | — | 42.6% | 61.2% |
| FY2024 | $179.3M | $17.5M | $0.99 | — | 13.5% | 853.5% |
| FY2023 | $116.9M | -$25.1M | -$0.14 | — | -17.5% | -2339.2% |
| FY2022 | $120.2M | -$58.6M | -$0.34 | -$74.2M | -46.2% | -333.4% |
| FY2021 | $149.2M | -$17.9M | -$0.11 | $5.3M | -8.4% | -37.6% |
| FY2020 | $108.6M | -$29.7M | -$0.18 | -$53.4M | -26.7% | -62.7% |
| FY2019 | $59.3M | -$66.9M | -$0.40 | -$43.0M | -116.5% | -110.5% |
| FY2018 | $44.5M | -$70.5M | — | -$59.9M | -163.3% | — |
| FY2017 | $4.5M | -$78.0M | — | -$77.7M | -1775.6% | — |
| FY2016 | $20.4M | -$69.2M | — | -$76.7M | -342.2% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
RIGEL PHARMACEUTICALS INC is a consistent compounder, expanding top-line revenue at 34.5% annually over the past decade.
RIGEL PHARMACEUTICALS INC has historically struggled to out-earn its cost of capital, averaging just -24.0% ROIC.
RIGEL PHARMACEUTICALS INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, RIGEL PHARMACEUTICALS INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $647.04 per share.